PROPACET 100
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROPACET 100 (PROPACET 100).
Propacet 100 is a prodrug of acetaminophen; it is hydrolyzed to acetaminophen, which inhibits cyclooxygenase (COX) and modulates the endogenous cannabinoid system, leading to analgesic and antipyretic effects.
| Metabolism | Rapidly hydrolyzed by plasma esterases to acetaminophen; acetaminophen is primarily metabolized by glucuronidation and sulfation, with a minor pathway via CYP2E1 to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). |
| Excretion | Propacet 100 (propacetamol) is a prodrug of acetaminophen. Renal elimination accounts for >90% of the administered dose, with approximately 85% as acetaminophen glucuronide and sulfate conjugates, and about 5% as unchanged acetaminophen. Biliary/fecal elimination is minimal (<5%). |
| Half-life | The terminal elimination half-life of acetaminophen after propacetamol administration is approximately 2–3 hours in adults with normal hepatic function. This half-life may be prolonged in patients with hepatic impairment or overdose. |
| Protein binding | Acetaminophen is minimally bound to plasma proteins, with protein binding of approximately 10–25% at therapeutic concentrations. It binds primarily to albumin. |
| Volume of Distribution | The volume of distribution (Vd) of acetaminophen is approximately 0.9–1.0 L/kg, indicating distribution into total body water. This reflects its hydrophilic nature and widespread tissue penetration. |
| Bioavailability | Propacetamol is administered intravenously; thus, bioavailability is 100%. After hydrolysis to acetaminophen, the bioavailability of active acetaminophen is essentially complete. |
| Onset of Action | Intravenous administration: Onset of analgesia occurs within 5–10 minutes after the start of infusion. Peak effect is observed at approximately 1 hour. |
| Duration of Action | Duration of analgesia is approximately 4–6 hours following intravenous administration. Clinical effect correlates with plasma acetaminophen concentrations above therapeutic threshold. |
1-2 tablets (100-200 mg propacetamol) orally every 4-6 hours; maximum 8 tablets (800 mg) per day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: extend interval to every 8 hours; GFR <30 mL/min: extend interval to every 12 hours; hemodialysis: dose post-dialysis. |
| Liver impairment | Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: use alternative analgesic. |
| Pediatric use | 10-15 mg/kg/dose propacetamol equivalent every 6 hours; maximum 60 mg/kg/day; do not exceed adult dose. |
| Geriatric use | Initiate at lower end of dosing range (100 mg every 6 hours); maximum 800 mg/day; monitor renal and hepatic function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROPACET 100 (PROPACET 100).
| Breastfeeding | Paracetamol is excreted into breast milk in trace amounts; milk-to-plasma ratio (M/P) is approximately 0.1-0.2. At maternal therapeutic doses, infant exposure is less than 2% of maternal weight-adjusted dose, considered compatible with breastfeeding. |
| Teratogenic Risk | Propacet 100 (propacetamol) is a prodrug of paracetamol (acetaminophen). First trimester: Limited human data, no increased risk of major malformations in large cohort studies. Second and third trimesters: No known fetal toxicity at therapeutic doses; overdose may cause hepatic necrosis in mother and potentially fetus. |
■ FDA Black Box Warning
No FDA black box warning exists for propacetamol specifically; however, acetaminophen (active metabolite) carries a risk of severe liver injury in cases of overdose, particularly with chronic alcohol use or hepatic impairment.
| Serious Effects |
History of hypersensitivity to acetaminophen or propacetamol; severe hepatic impairment; use of MAOIs (potential interaction).
| Precautions | Hepatotoxicity risk with overdose or chronic alcohol use; severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) reported rarely; use with caution in hepatic impairment, alcohol use disorder, or malnutrition. |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver function tests (ALT, AST) if prolonged use or overdose suspected. For chronic or high-dose use, assess fetal growth via ultrasound. No specific fetal monitoring required for short-term therapeutic doses. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies show no impairment of fertility at clinical doses. |